share_log

BRIEF-IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics

BRIEF-IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics

Brief-IX Biophma表示與Seelos治療公司達成獨家許可協議
reuters ·  2021/11/24 14:10

Nov 24 (Reuters) - IX Biopharma Ltd IXBI.SI :

路透11月24日電-IX Biophma Ltd IXBI.SI:

* ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH SEELOS THERAPEUTICS

*與SEELOS治療公司簽訂獨家許可協議

* WILL RECEIVE US$9 MILLION UPFRONT PAYMENT TO BE SATISFIED IN CASH AND SHARES

*將收到900萬美元的預付款,以現金和股票支付

* ALSO ELIGIBLE FOR UP TO US$239 MILLION IN MILESTONE PAYMENTS AS PART OF DEAL

*作為交易的一部分,還有資格獲得高達2.39億美元的里程碑付款

Source text for Eikon: ID:nSN4DNx5y Further company coverage: IXBI.SI

Eikon的源文本:ID:nSN4DNx5y進一步的公司報道:IXBI.SI

((Reuters.Briefs@thomsonreuters.com;))

(Reurs.Briefs@thomsonreurs.com;)

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論